ALK chief: We need to expand our focus
Allergy drug group ALK wants to be more than just a niche company in the immunotherapy field. Thus, 50 employees are now working on a new strategy for how the company can expand and become “a real allergy company” with a broader focus, says CEO Carsten Hellmann.
BY LONNI LYNGE
The Danish drug group ALK may be known as an “allergy giant”. However, this reputation is more or less limited to its home country.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK CEO: We must hit it out of the park
For abonnenter
ALK's house dust mite tablet approved in Canada
For abonnenter
ALK-director: Important strategic approval
For abonnenter
